Daigo Asano

710 total citations
19 papers, 527 citations indexed

About

Daigo Asano is a scholar working on Molecular Biology, Oncology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Daigo Asano has authored 19 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Daigo Asano's work include Chemical Synthesis and Analysis (3 papers), Neuroscience and Neuropharmacology Research (3 papers) and Sirtuins and Resveratrol in Medicine (3 papers). Daigo Asano is often cited by papers focused on Chemical Synthesis and Analysis (3 papers), Neuroscience and Neuropharmacology Research (3 papers) and Sirtuins and Resveratrol in Medicine (3 papers). Daigo Asano collaborates with scholars based in Japan, United States and Germany. Daigo Asano's co-authors include Takahiro Mukai, Hideo Saji, Seigo Ishino, Mikako Ogawa, Masashi Shiomi, Nobuyuki Kudomi, Yasuhiro Magata, Noboru Teramoto, Hidehiro Iida and Hiroshi Watabe and has published in prestigious journals such as Angewandte Chemie International Edition, Atherosclerosis and Drug Metabolism and Disposition.

In The Last Decade

Daigo Asano

19 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daigo Asano Japan 9 189 186 140 103 84 19 527
Tobias von Lukowicz Switzerland 11 95 0.5× 95 0.5× 149 1.1× 157 1.5× 180 2.1× 11 555
Patrick Hu United States 11 118 0.6× 78 0.4× 247 1.8× 94 0.9× 209 2.5× 30 672
Valeria Pecce Italy 18 77 0.4× 75 0.4× 448 3.2× 88 0.9× 32 0.4× 43 1.0k
G. Tartarelli Italy 9 38 0.2× 136 0.7× 120 0.9× 41 0.4× 40 0.5× 18 444
Yiqian Liang China 14 38 0.2× 61 0.3× 329 2.4× 84 0.8× 21 0.3× 34 511
Alex Bell United Kingdom 10 23 0.1× 71 0.4× 354 2.5× 80 0.8× 119 1.4× 12 637
Mary E. Duffy United States 7 110 0.6× 59 0.3× 198 1.4× 17 0.2× 152 1.8× 8 486
Elisavet Paplomata United States 9 49 0.3× 158 0.8× 359 2.6× 28 0.3× 20 0.2× 14 708
Zhengrong Huang China 8 18 0.1× 158 0.8× 187 1.3× 47 0.5× 74 0.9× 11 427
Yu Gan China 16 65 0.3× 322 1.7× 372 2.7× 52 0.5× 17 0.2× 42 730

Countries citing papers authored by Daigo Asano

Since Specialization
Citations

This map shows the geographic impact of Daigo Asano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daigo Asano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daigo Asano more than expected).

Fields of papers citing papers by Daigo Asano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daigo Asano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daigo Asano. The network helps show where Daigo Asano may publish in the future.

Co-authorship network of co-authors of Daigo Asano

This figure shows the co-authorship network connecting the top 25 collaborators of Daigo Asano. A scholar is included among the top collaborators of Daigo Asano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daigo Asano. Daigo Asano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Yamamura, Naotoshi, Hideo Takakusa, Daigo Asano, et al.. (2024). Tissue distribution of renadirsen sodium, a dystrophin exon-skipping antisense oligonucleotide, in heart and diaphragm after subcutaneous administration to cynomolgus monkeys. Nucleosides Nucleotides & Nucleic Acids. 44(8). 626–642. 1 indexed citations
2.
Asano, Daigo, Hideo Takakusa, & Daisuke Nakai. (2023). Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. Pharmaceutics. 16(1). 47–47. 15 indexed citations
3.
Hayashi, Noriyuki, Sayaka Suzuki, Kyosuke Tanaka, et al.. (2023). N-Aryl Indoles as a Novel Class of Potent NaV1.7 Inhibitors. ACS Medicinal Chemistry Letters. 14(6). 788–793. 3 indexed citations
4.
5.
Asano, Daigo, Hamim Zahir, Hideyuki Shiozawa, et al.. (2021). CYP2C8-Mediated Formation of a Human Disproportionate Metabolite of the Selective NaV1.7 Inhibitor DS-1971a, a Mixed Cytochrome P450 and Aldehyde Oxidase Substrate. Drug Metabolism and Disposition. 50(3). 235–242. 5 indexed citations
6.
Tsuji, Takashi, Yoshitaka Sogawa, Koji Terayama, et al.. (2021). Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition. Bioorganic & Medicinal Chemistry Letters. 43. 128048–128048. 9 indexed citations
7.
Ito, Kentaro, Hideo Takakusa, Masayo Kakuta, et al.. (2021). Renadirsen, a Novel 2′OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo. Current Issues in Molecular Biology. 43(3). 1267–1281. 13 indexed citations
8.
Tsuji, Takashi, Yoshitaka Sogawa, Koji Terayama, et al.. (2021). Discovery of DS68702229 as a Potent, Orally Available NAMPT (Nicotinamide Phosphoribosyltransferase) Activator. Chemical and Pharmaceutical Bulletin. 69(11). 1110–1122. 10 indexed citations
9.
10.
Asano, Daigo, Takahiro Shibayama, Hideyuki Shiozawa, et al.. (2021). Evaluation of species differences in the metabolism of the selective NaV1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase. Xenobiotica. 51(9). 1060–1070. 5 indexed citations
11.
Furukawa, Akihiro, Joshua Schwochert, Cameron R. Pye, et al.. (2020). Drug‐Like Properties in Macrocycles above MW 1000: Backbone Rigidity versus Side‐Chain Lipophilicity. Angewandte Chemie International Edition. 59(48). 21571–21577. 52 indexed citations
12.
Furukawa, Akihiro, Joshua Schwochert, Cameron R. Pye, et al.. (2020). Drug‐Like Properties in Macrocycles above MW 1000: Backbone Rigidity versus Side‐Chain Lipophilicity. Angewandte Chemie. 132(48). 21755–21761. 7 indexed citations
13.
Tanaka, Kyosuke, Hiroyuki Kobayashi, Sayaka Suzuki, et al.. (2020). Discovery of a Novel Class of State-Dependent Na<sub>V</sub>1.7 Inhibitors for the Treatment of Neuropathic Pain. Chemical and Pharmaceutical Bulletin. 68(7). 653–663. 4 indexed citations
14.
Suzuki, Sayaka, Takeshi Kuroda, Kazufumi Kubota, et al.. (2015). Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(22). 5419–5423. 5 indexed citations
15.
Ishino, Seigo, Takahiro Mukai, Noriaki Kume, et al.. (2007). Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability—analysis in hypercholesterolemic rabbits. Atherosclerosis. 195(1). 48–56. 73 indexed citations
16.
Hanaoka, Hirofumi, Takahiro Mukai, Daigo Asano, et al.. (2007). Chemical design of a radiolabeled gelatinase inhibitor peptide for the imaging of gelatinase activity in tumors. Nuclear Medicine and Biology. 34(5). 503–510. 28 indexed citations
17.
Kobayashi, Hideo, et al.. (2007). Establishment of Evaluation Method for siRNA Delivery Using Stable Cell Line Carrying the Luciferase Reporter Gene. Biological and Pharmaceutical Bulletin. 30(10). 1844–1850. 5 indexed citations
18.
Ogawa, Kazuma, Takahiro Mukai, Daigo Asano, et al.. (2007). Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.. PubMed. 48(1). 122–7. 37 indexed citations
19.
Ogawa, Mikako, Seigo Ishino, Takahiro Mukai, et al.. (2004). (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study.. PubMed. 45(7). 1245–50. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias von Lukowicz Breakdown of academic impact, for papers by Patrick Hu Breakdown of academic impact, for papers by Valeria Pecce Breakdown of academic impact, for papers by G. Tartarelli Breakdown of academic impact, for papers by Yiqian Liang Breakdown of academic impact, for papers by Alex Bell Breakdown of academic impact, for papers by Mary E. Duffy Breakdown of academic impact, for papers by Elisavet Paplomata Breakdown of academic impact, for papers by Zhengrong Huang Breakdown of academic impact, for papers by Yu Gan
Rankless by CCL
2026